Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
IAS 2007: Sydney, Australia; July 22-25

Key Links:

By Topic:

Search:

  
  • Email Email
  • Glossary Glossary

IAS 2007: Index of Coverage

Daily Summaries

Joel Gallant, M.D.
  • IAS 2007: Day Three & Conference Roundup
    Joel Gallant, M.D., M.P.H., wraps up our daily recap series with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.
  • Daniel Berger, M.D.
  • IAS 2007: Day Two
    Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
  • Daniel Berger, M.D.
  • IAS 2007: Day One
    Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
  • Antiretrovirals in Development
    Complications of HIV/HAART
    HIV Drug Resistance
    • Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
      It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
      In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
    • News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
      With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
      In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
    First-Line/Second-Line Therapy
    • Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment (July 25, 2007)
      For the first time, a drug has been found that matches the potency of lopinavir/ritonavir in second-line and third-line patients, and which might potentially even outperform lopinavir/ritonavir in certain numbers of those patients. All without compromising safety and tolerability, and apparently without paying resistance consequences if virologic failure occurs. Edwin DeJesus, M.D., reports.
      In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
    • ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
      Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
      In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
    • Switching to NRTIs Less Associated With Lipoatrophy Is Successful (July 25, 2007)
      Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
      In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
    • New Research on Pediatric HIV Infection (July 24, 2007)
      Available as a Webcast, podcast and transcript.
      From kaisernetwork.org
    • Treatment of Early HIV Disease (July 23, 2007)
      From kaisernetwork.org
    International
    Pathogenesis
    Pediatric Treatment
    HIV Prevention
    Protests & Activism
    Women & HIV
    Other News and Research
    Opening Session
    Pre-Conference News

      
    • Email Email
    • Glossary Glossary

    Advertisement